Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial ...

The risk for respiratory syncytial virus-related hospitalizations is elevated in children with chronic medical conditions ...

Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract ...

The rate of atrial fibrillation was also higher in RSV patients, although it depended on preexisting heart conditions and ...

Professor Margie Danchin addresses declining childhood vaccination rates and vaccine hesitancy through trust-building ...

Vaccinating pregnant women against respiratory syncytial virus (RSV) is linked to a 72% drop in newborns being hospitalized ...

Children hospitalized with RSV showed higher risk for ICU admission, IMV, and supplemental oxygen than children hospitalized with COVID-19 or influenza.

Modern medicine is largely reactive—treating illness only after symptoms emerge. But a new study from the Research Institute ...

British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that ...

UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its ...